Interventional device developer Guidant reported that it has received European CE Mark approval for its Xience V everolimus-eluting coronary stent.
Everolimus has been shown to reduce tissue proliferation in the coronary vessels following stent implantation, according to the Indianapolis-based firm.
Guidant said it would begin marketing the stent in the 25 countries of the European Union. In addition, the firm said that CE Mark approval is used to support market registrations in other countries including those within Asia, Latin America, and Eastern Europe.
By AuntMinnie.com staff writers
February 1, 2006
Related Reading
Guidant sales fall in Q4, January 27, 2006
Guidant expects Q4 sales downturn, January 10, 2006
Guidant schedules J&J vote, December 30, 2005
FDA says Guidant reports more device failures, December 30, 2005
FDA issues warning to Guidant, December 27, 2005
Copyright © 2006 AuntMinnie.com
